Laboratory Corp Of America Holdings (LH): David P King , President & CEO of Laboratory Corp Of America Holdings sold 196,400 shares on Jun 13, 2016. The Insider selling transaction was reported by the company on Jun 15, 2016 to the Securities and Exchange Commission. The shares were sold at $128.42 per share for a total value of $25139148 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 13, 2016, Lisa J Uthgenannt (Chief Human Resources Officer) sold 3,740 shares at $125.17 per share price.On Apr 29, 2016, Edward T Dodson (Principal Accounting Officer) sold 9,392 shares at $126.42 per share price.Also, On Mar 15, 2016, James T. Jr. Boyle (EVP,CEO of LabCorp Diagnostics) sold 1,543 shares at $115.32 per share price.On Mar 15, 2016, F Samuel Iii Eberts (Chief Legal Officer, Secretary) sold 309 shares at $115.32 per share price.
Shares of LABORATORY CORP OF AMERICA COM (LH) ended Wednesday, Jun 15, 2016 session in red amid volatile trading. The shares closed down -1.4 points or -1.10% at $126.39 with 7,20,574 shares getting traded. Post opening the session at $128.08, the shares hit an intraday low of $126.26 and an intraday high of $128.43 and the price vacillated in this range throughout the day. The company has a market cap of $12,942 M and the number of outstanding shares has been calculated to be 10,24,00,000 shares. The 52-week high of LABORATORY CORP OF AMERICA COM is $131.99 and the 52-week low is $97.79.
Company has been under the radar of several Street Analysts.LABORATORY CORP OF AMERICA COM is Reiterated by Mizuho to Neutral and the brokerage firm has raised the Price Target to $ 132 from a previous price target of $119 .The Rating was issued on Apr 26, 2016.LABORATORY CORP OF AMERICA COM is Reiterated by Canaccord Genuity to Buy and the brokerage firm has raised the Price Target to $ 140 from a previous price target of $135 .The Rating was issued on Apr 26, 2016.LABORATORY CORP OF AMERICA COM is Reiterated by Barclays to Overweight and the brokerage firm has raised the Price Target to $ 155 from a previous price target of $152 .The Rating was issued on Apr 26, 2016.
Laboratory Corporation of America Holdings is an independent clinical laboratory company in the United States. Through a national network of laboratories the Company offers a range of clinical laboratory tests that are used by the medical profession in core testing patient diagnosis and in the monitoring and treatment of disease. The Company manages its operations through two segments: the Clinical diagnostics laboratory segment which includes core testing as well as genomic and esoteric testing; and the Other segment which consists of the Company’s non-United States clinical diagnostic laboratory operations in Ontario Canada. It also provides specialty testing services in the areas of allergy clinical trials diagnostic genetics women’s health cardiovascular disease identity forensics infectious disease endocrinology oncology coagulation occupational testing and pain management.